Nasdaq

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

SAN DIEGO, Dec. 5, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for ...
Healio

Crinecerfont approved to treat congenital adrenal hyperplasia

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...
Medscape

‘Game Changer’ Approved for Congenital Adrenal Hyperplasia

The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...
Nasdaq

Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules and oral solution as an adjunctive treatment to ...
FiercePharma

Neurocrine spotlights challenges of congenital adrenal hyperplasia patients with ‘What the C@H?!’ campaign

Neurocrine Biosciences’ newest educational campaign wants frustrated congenital adrenal hyperplasia patients to ask, “What the C@H?!” Neurocrine unveiled the campaign this week, not long after ...
Healio

Crenessity benefits continue for adults, children with congenital adrenal hyperplasia

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
BioWorld

Blockbuster bound? Neurocrine’s hyperplasia drug approved

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...
Medscape

Male Bone Health at Risk in Congenital Adrenal Hyperplasia

Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and experiencing a ...
MedPage Today

Fertility Struggles Common in Classic Congenital Adrenal Hyperplasia

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...
MedPage Today

Classic Congenital Adrenal Hyperplasia Treatment Hard on the Bones

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...
Seeking Alpha

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinecerfont New Drug Application Submission Planned in 2024 NBI-'770, an Oral NMDA NR2B Negative Allosteric ...